Загрузка...
Antibody-drug conjugates: Present and future
Antibody-drug conjugates (ADCs) are becoming an increasingly important sub-class of antibody-related therapeutics. Two ADCs, brentuximab vedotin (Adcetris®) and ado-trastuzumab emtansine (Kadcyla®), were recently approved for marketing both by the US Food and Drug Administration (FDA) and the Europe...
Сохранить в:
| Опубликовано в: : | MAbs |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Taylor & Francis
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7098595/ https://ncbi.nlm.nih.gov/pubmed/24423577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.27436 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|